Q2 2026 saw 11% TRCV growth and 4% revenue growth year-over-year, with Adjusted Net Income at $6.9 million and Adjusted EBITDA margin at 27%. The company declared a $0.16 dividend and is positioned for a strong second half of 2026.Original document: NRC Health [NRC] SEC 8-K Current Report — Jul. 28…
Q2 2026 saw 11% TRCV growth and 4% revenue growth year-over-year, with Adjusted Net Income at $6.9 million and Adjusted EBITDA margin at 27%. The company declared a $0.16 dividend and is positioned for a strong second half of 2026.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
